Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts
Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts
复制标题
经导管动脉栓塞随后使用奥曲肽和塞来昔布可协同延长 VX2 同种异体肝移植兔的生存期。
DOI：
10.1111/1751-2980.12001
复制
发表时间：
2013-01-01
影响因子：
3.5
通讯作者：
Tang, Cheng Wei
中科院分区：
文献类型：
--
作者：
Tong, Huan;Li, Xiao;Tang, Cheng Wei
目的：目的：探讨经导管动脉栓塞（TAE）联合奥曲肽和塞来昔布（O + C）治疗兔肝移植瘤（VX 2）的疗效，为临床治疗提供依据。结果：TAE + O + C组兔生存时间较对照组延长近20 d，TAE + O + C组兔生存时间较对照组延长近20 d。TAE + O + C组80 d存活率为50%，为4组中最高（P < 0.05）。对照组中没有携带VX 2同种异体移植物的兔存活超过60天。与对照组相比，其他两个干预组的生存时间均无显著延长（P > 0.05）。TAE + O + C组TAE诱导的CD 31表达明显降低（P < 0.05）。结论：TAE联合奥曲肽和塞来昔布可通过抑制新生血管生成、抑制肿瘤生长和转移，协同延长兔肝移植VX 2的存活时间。
OBJECTIVE: To validate the efficacy of an innovative multimodality therapy with transcatheter arterial embolization (TAE) plus octreotide and celecoxib in reducing neoangiogenesis and prolonging the survival of rabbits with hepatocellular carcinoma.METHODS: Rabbits with hepatic VX2 allografts were divided into four groups: control group, TAE group, octreotide + celecoxib (O + C) group and the multimodality therapy (TAE + O + C) group. Survival of the rabbits was analyzed using the Kaplan-Meier method and the expression of CD31 in tumor tissues was detected by immunohistochemistry.RESULTS: Rabbits in the TAE + O + C group lived nearly 20 days longer than those in the control group. The survival rate of the TAE + O + C group was 50% at day 80 and was the highest among the four groups (P < 0.05). No VX2 allograft-bearing rabbits in the control group lived longer than 60 days. Compared with the control group, the survival time of the other two intervention groups were not prolonged significantly (P > 0.05). The CD31 expression induced by TAE was reduced significantly in TAE + O + C group (P < 0.05). Less metastasiswas detected in TAE + O + C group.CONCLUSION: TAE followed by the long-term administration of octreotide and celecoxib can synergistically prolong the survival of rabbits with hepatic VX2 allografts by inhibiting potential neoangiogenesis, tumor growth and metastasis.